Predict your next investment

Venture Capital
BUSINESS PRODUCTS & SERVICES | Consulting & Outsourcing / Research, Engineering & Technical
oxfordsciencesinnovation.com

See what CB Insights has to offer

Investments

93

Portfolio Exits

6

Funds

1

Partners & Customers

7

Service Providers

1

About Oxford Sciences Innovation

Oxford Sciences Innovation aims to support high tech startups looking to spin out of the University of Oxford.

Oxford Sciences Innovation Headquarter Location

King Charles House Park End Street

Oxford, England, OX1 1JD,

United Kingdom

+44 01865 950 000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Oxford Sciences Innovation Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Oxford Sciences Innovation Rank

Latest Oxford Sciences Innovation News

Ultromics’ $33 Million Series B Funding

Aug 24, 2021

Fieldfisher has advised Ultromics on the deal. The $33 million Series B funding round was led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation. Founded in 2017 by Dr Ross Upton and Professor Paul Leeson, as a spin out from the University of Oxford and built-in partnership with the U.K.’s National Health Service (NHS). Ultromics’ EchoGo Core and EchoGo Pro platforms quickly deliver highly accurate assessments of heart function that support the diagnosis of coronary artery disease, heart failure and amyloidosis. Ultromics provides autonomous echocardiography analysis through innovative AI solutions, giving accurate decisions when diagnosing cardiovascular disease, the leading cause of mortality in the world. Echocardiography is the most cost efficient and safest way of imaging of the heart and Ultromics’ revolutionary AI technology improves the accuracy allowing it to be equally effective to alternatives that are more expensive. Ultromics plans to use the Series B funding to accelerate validating and scaling their technology with the support of their investors. Dr. Janita Good (Picture), co-head of Life Sciences at Fieldfisher led on the deal.

Oxford Sciences Innovation Investments

93 Investments

Oxford Sciences Innovation has made 93 investments. Their latest investment was in Ultromics as part of their Series B on August 8, 2021.

CBI Logo

Oxford Sciences Innovation Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/16/2021

Series B

Ultromics

$33M

No

8

8/5/2021

Series B

PepGen

$112.5M

No

5

7/30/2021

Series A - II

Rey

$10M

No

1

7/20/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

5/24/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/16/2021

8/5/2021

7/30/2021

7/20/2021

5/24/2021

Round

Series B

Series B

Series A - II

Series B

Seed VC

Company

Ultromics

PepGen

Rey

Subscribe to see more

Subscribe to see more

Amount

$33M

$112.5M

$10M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

8

5

1

10

10

Oxford Sciences Innovation Portfolio Exits

6 Portfolio Exits

Oxford Sciences Innovation has 6 portfolio exits. Their latest portfolio exit was YASA on July 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/22/2021

Acquired

9

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/22/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

9

10

10

10

10

Oxford Sciences Innovation Fund History

1 Fund History

Oxford Sciences Innovation has 1 fund, including Oxford Sciences Innovation.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/9/2016

Oxford Sciences Innovation

$729.46M

4

Closing Date

12/9/2016

Fund

Oxford Sciences Innovation

Fund Type

Status

Amount

$729.46M

Sources

4

Oxford Sciences Innovation Partners & Customers

7 Partners and customers

Oxford Sciences Innovation has 7 strategic partners and customers. Oxford Sciences Innovation recently partnered with AstraZeneca on November 11, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

11/4/2020

Partner

AstraZeneca

United Kingdom

Oxford University breakthrough on global COVID-19 vaccine

A key element of Oxford University 's partnership with AstraZeneca plc is the joint commitment to provide the vaccine on a not-for-profit basis for the duration of the pandemic across the world , and in perpetuity to low - and middle-income countries .

3

1/11/2018

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

12/11/2017

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

12/11/2017

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

2/21/2017

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

11/4/2020

1/11/2018

12/11/2017

12/11/2017

2/21/2017

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

AstraZeneca

Country

United Kingdom

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Oxford University breakthrough on global COVID-19 vaccine

A key element of Oxford University 's partnership with AstraZeneca plc is the joint commitment to provide the vaccine on a not-for-profit basis for the duration of the pandemic across the world , and in perpetuity to low - and middle-income countries .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Oxford Sciences Innovation Service Providers

1 Service Provider

Oxford Sciences Innovation has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Investment Bank

Bookrunner

Service Provider

Associated Rounds

Provider Type

Investment Bank

Service Type

Bookrunner

Partnership data by VentureSource

Oxford Sciences Innovation Team

4 Team Members

Oxford Sciences Innovation has 4 team members, including current Chief Executive Officer, Alexis Dormandy.

Name

Work History

Title

Status

Alexis Dormandy

RED, Orange, Orange, and Virgin Group

Chief Executive Officer

Current

Alexis Zervoglos

Qardio, Commerzbank, Dresdner Kleinwort Wasserstein Online Markets Technology Investments, and Cambridge Display Technology

Chief Investment Officer

Current

Charles Conn

Chief Executive Officer

Former

Claire Brown

Chief Investment Officer

Former

Name

Alexis Dormandy

Alexis Zervoglos

Charles Conn

Claire Brown

Work History

RED, Orange, Orange, and Virgin Group

Qardio, Commerzbank, Dresdner Kleinwort Wasserstein Online Markets Technology Investments, and Cambridge Display Technology

Title

Chief Executive Officer

Chief Investment Officer

Chief Executive Officer

Chief Investment Officer

Status

Current

Current

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.